Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.

2.50
Hdl Handle:
http://hdl.handle.net/10541/77965
Title:
Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.
Authors:
Paisley, Angela N; Trainer, Peter J; Drake, William M
Abstract:
Pegvisomant is a pegylated analogue of growth hormone (GH) that functions as a growth hormone receptor antagonist. Clinical trials of its use in acromegaly commenced in 1997; the drug was approved in the US in March 2003 and in Europe in November 2003. In the same year, it was made available on prescription in several European countries, with further launches due in 2004. Pegvisomant is capable of normalising serum insulin-like growth factor-I concentrations (the chief mediator of disease activity in acromegaly) in 97% of patients with active acromegaly, and therapy is associated with a significant improvement in the symptoms and signs of GH excess. Disease control is achievable with pegvisomant in patients who are wholly or partially resistant or do not tolerate somatostatin analogues; preliminary data suggest that the drug may be particularly suitable for patients with acromegaly and co-existent diabetes mellitus.
Affiliation:
Department of Endocrinology, Christie Hospital, Manchester, UK.
Citation:
Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly. 2004, 4 (3):421-5 Expert Opin Biol Ther
Journal:
Expert Opinion on Biological Therapy
Issue Date:
Mar-2004
URI:
http://hdl.handle.net/10541/77965
DOI:
10.1517/14712598.4.3.421
PubMed ID:
15006735
Type:
Article
Language:
en
ISSN:
1471-2598
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorPaisley, Angela N-
dc.contributor.authorTrainer, Peter J-
dc.contributor.authorDrake, William M-
dc.date.accessioned2009-08-20T11:31:19Z-
dc.date.available2009-08-20T11:31:19Z-
dc.date.issued2004-03-
dc.identifier.citationPegvisomant: a novel pharmacotherapy for the treatment of acromegaly. 2004, 4 (3):421-5 Expert Opin Biol Theren
dc.identifier.issn1471-2598-
dc.identifier.pmid15006735-
dc.identifier.doi10.1517/14712598.4.3.421-
dc.identifier.urihttp://hdl.handle.net/10541/77965-
dc.description.abstractPegvisomant is a pegylated analogue of growth hormone (GH) that functions as a growth hormone receptor antagonist. Clinical trials of its use in acromegaly commenced in 1997; the drug was approved in the US in March 2003 and in Europe in November 2003. In the same year, it was made available on prescription in several European countries, with further launches due in 2004. Pegvisomant is capable of normalising serum insulin-like growth factor-I concentrations (the chief mediator of disease activity in acromegaly) in 97% of patients with active acromegaly, and therapy is associated with a significant improvement in the symptoms and signs of GH excess. Disease control is achievable with pegvisomant in patients who are wholly or partially resistant or do not tolerate somatostatin analogues; preliminary data suggest that the drug may be particularly suitable for patients with acromegaly and co-existent diabetes mellitus.en
dc.language.isoenen
dc.subjectPituitary Canceren
dc.subject.meshAcromegaly-
dc.subject.meshAnimals-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshInsulin Resistance-
dc.subject.meshPituitary Neoplasms-
dc.subject.meshReceptors, Somatotropin-
dc.titlePegvisomant: a novel pharmacotherapy for the treatment of acromegaly.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital, Manchester, UK.en
dc.identifier.journalExpert Opinion on Biological Therapyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.